Research programme: ion channel antagonists - Asahi Kasei Pharma/ Evotec AG
Latest Information Update: 31 Jan 2017
At a glance
- Originator Asahi Kasei Pharma Corp; Evotec AG
- Developer Asahi Kasei; Evotec AG
- Mechanism of Action Ion channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified